Viridian Therapeutics, Inc.
VRDN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $71 | $0 | $0 | $0 |
| % Growth | 93,993.3% | 4.2% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $71 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $86 | $87 | $77 | $72 |
| G&A Expenses | $24 | $20 | $17 | $16 |
| SG&A Expenses | $24 | $20 | $17 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $111 | $107 | $94 | $88 |
| Operating Income | -$40 | -$107 | -$94 | -$87 |
| % Margin | -56.7% | -142,356% | -130,369.4% | -121,488.9% |
| Other Income/Exp. Net | $5 | $6 | $7 | $8 |
| Pre-Tax Income | -$35 | -$101 | -$87 | -$80 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$35 | -$101 | -$87 | -$80 |
| % Margin | -49% | -134,313.3% | -120,711.1% | -110,729.2% |
| EPS | -0.34 | -1 | -0.87 | -0.81 |
| % Growth | 66% | -14.9% | -7.4% | – |
| EPS Diluted | -0.34 | -1 | -0.87 | -0.81 |
| Weighted Avg Shares Out | 82 | 82 | 81 | 80 |
| Weighted Avg Shares Out Dil | 82 | 82 | 81 | 80 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $7 | $8 | $9 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$34 | -$100 | -$86 | -$79 |
| % Margin | -48.1% | -133,477.3% | -119,734.7% | -109,366.7% |